Clinical trials: HFpEF
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy
This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber…
- Trial name
- PACE-nHCM (NCT06775886)
- Testing
- myPACE+ algorithm
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
The purpose of this clinical study is to assess the safety and effectiveness of the Atrial Flow Regulator in the treatment of subjects, 18 years of age or older, who have symptomatic heart failure with preserved ejection fraction…
- Trial name
- FROST-HF (NCT05136820)
- Testing
- Atrial Flow Regulator
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Occlutech International AB
Heart Failure With Preserved Ejection Fraction (HFpEF)
Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition
The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT04822649
- Testing
- Adenosine stress echocardiography with the evaluation of coronary artery blood flow
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Korea University Anam Hospital
Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction
Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study
This study is designed to evaluate the safety, feasibility, and effectiveness of a 12-week eccentric exercise program for older adults with sarcopenia (muscle loss) or sarcopenic obesity and chronic heart failure (HF).
- Conditions
- Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction, Sarcopenia in Elderly, Sarcopenic Obesity
- Trial name
- ECLYPSE-HF (NCT06826963)
- Testing
- Aerobic eccentric intervention
- Where
- 2 sites in Italy
- Volunteers
- 15 people
- Sponsor
- Universita di Verona
Congestive Heart Failure, Volume Overload
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
The purpose of this study is to analyze the utility of a novel five-point ultrasound as a predictor of volume overload in diverse patients who are admitted with volume overload/congestive heart failure (CHF) exacerbation at…
- Trial name
- BUDS-HF (NCT07096726)
- Testing
- Five-point ultrasound, Standard of care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boston Medical Center
Heart Failure, Obesity
Biomarkers in Patients With Suspected HFpEF
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1.
- Conditions
- Heart Failure, Obesity, Heart Failure With Preserved Ejection Fraction
- Trial name
- BIOPEF (NCT06101693)
- Testing
- Plasma biomarker levels
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,028 people
- Sponsor
- NHS Greater Glasgow and Clyde
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
- Trial name
- NCT07864558
- Testing
- Individualized myPACE pacemaker programming
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tufts Medical Center
HFpEF - Heart Failure With Preserved Ejection Fraction
Role of Colchicine as Anti-Inflammatory Therapy in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a condition associated with high morbidity and mortality. Chronic low-grade inflammation plays a key role in its progression, yet few treatments specifically target this…
- Trial name
- CO-HFpEF (NCT06837623)
- Testing
- Colchicine Tablets
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Cairo University
Heart Failure With Preserved Ejection Fraction (HFpEF)
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction…
- Trial name
- NCT03877224
- Testing
- Dapagliflozin
- Where
- 101 sites in United States, Argentina and 10 more
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Heart Failure, Systolic, Heart Failure, Diastolic
Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure
ITISHOPE4HF is a randomized controlled trial of telerehabilitation in a heart failure population. The goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients.
- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic, Chronic Kidney Diseases, Cardiorenal Syndrome
- Trial name
- ITISHOPE4HF (NCT03183323)
- Testing
- Telerehabilitation
- Where
- Norway
- Volunteers
- 61 people
- Sponsor
- Helse Nord-Trøndelag HF
Heart Failure With Preserved Ejection Fraction (HFpEF)
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
- Trial name
- NCT06560762
- Testing
- STM01
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Secretome Therapeutics
Chronic Heart Failure With Preserved Ejection Fraction
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after…
- Trial name
- VITALITY-HFpEF (NCT03547583)
- Testing
- Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
- Where
- 177 sites in United States, Argentina and 19 more
- Volunteers
- 789 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers
- Trial name
- NCT04232345
- Testing
- AZD4831
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.
- Trial name
- PIOHF (NCT05838287)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Heart Failure With Preserved Ejection Fraction
3-Month Home-based Training With Whole Body Vibration (WBV) Device in Patients With Heart Failure and Preserved Ejection Fraction (GALILEO-HFpEF-HOME) (GALILEOHOME)
In order to evaluate Long-term effects of whole Body Vibration (wbv) in patients with HFpEF patients will get a training device to use at home for 3 months.
- Trial name
- GALILEO-HFpEF (NCT04239807)
- Testing
- Group 1 GALILEO WBV, Group 2 Control
- Volunteers
- 60 people
- Sponsor
- Klinikum der Universität Köln
Heart Failure With Normal Ejection Fraction, Chronotropic Incompetence
β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)
The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and multifactorial. Chronotropic incompetence has emerged as a crucial mechanism, particularly in elderly patients.
- Trial name
- Preserve-HR (NCT03871803)
- Testing
- Controlled withdrawal of beta-blockers, Cardiopulmonary Exercise Testing
- Where
- Spain
- Volunteers
- 52 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
HFpEF
Muscle Blood Flow Regulation in HFpEF
Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System.
- Trial name
- NCT05115890
- Testing
- Exercise training
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Heart Failure
Rheos System for the Treatment of HFpEF Heart Failure
The purpose of this clinical investigation (NCT00957073) is to continue long-term follow-up of device arm subjects enrolled in the HOPE4HF Trial, utilizing the BAROSTIM NEO™ LEGACY device for Implantable Pulse Generator (IPG)…
- Trial name
- HOPE4HF (NCT00957073)
- Testing
- Rheos® system
- Where
- 22 sites in United States
- Volunteers
- 19 people
- Sponsor
- CVRx, Inc.